Sarepta Therapeutics
SRPT · Nasdaq · United States
Share price · SRPT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SRPT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Sep 2026+5.2%
Nothing announced by SRPT that day or the session before.
- 2 Sep 2026+8.8%
Nothing announced by SRPT that day or the session before.
- 27 Aug 2026+10.9%
Nothing announced by SRPT that day or the session before.
- 11 Aug 2026+6.1%
Nothing announced by SRPT that day or the session before.
- 3 Aug 2026+6.9%
Nothing announced by SRPT that day or the session before.
- 21 Jul 2026-3.7%
Nothing announced by SRPT that day or the session before.
- 30 Jun 2026+5.6%
Nothing announced by SRPT that day or the session before.
- 25 Jun 2026-4.0%
Nothing announced by SRPT that day or the session before.
- 24 Jun 2026-3.3%
Nothing announced by SRPT that day or the session before.
- 25 Mar 2026+35.0%
Nothing announced by SRPT that day or the session before.
Share of unusual movement by asset
For each asset, the share of SRPT's own-move activity since 13 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
SRP-1001events and moves
| 1 | shown from 8 days |
SRP-1003events and moves | 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 22% |
| Other company news (earnings, financing, releases naming no asset) | — | 2% |
| Sessions with no dated event | — | 76% |
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | DUX4RNA / oligonucleotide | Facioscapulohumeral Muscular Dystrophy | |
| Phase 1/2 | DMPK (dystrophia myotonica protein kinase)RNA / oligonucleotide | Myotonic Dystrophy Type 1 | |
| Phase 1 | ATXN2 (ataxin-2)RNA / oligonucleotide | Spinocerebellar Ataxia Spinocerebellar Ataxia Type 2 |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $381M | $83M | $473M+ $406M short-term inv. | $28M$60M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $401M | $91M | $571M+ $217M short-term inv. | $4.9M$197M operating cash flow | report ↗ |
| 2026-Q1 | $731M | $154M | $464M+ $189M short-term inv. | —-$203M operating cash flow | report ↗ |
| 2025-Q4 | $443M | — | $801M+ $138M short-term inv. | $412M$131M operating cash flow | report ↗ |
| 2025-Q3 | $399M | $219M | $613M+ $238M short-term inv. | $180M-$15M operating cash flow | report ↗ |
| 2025-Q2 | $611M | $204M | $511M+ $290M short-term inv. | —$261M operating cash flow | report ↗ |
| 2025-Q1 | $745M | $773M | $241M+ $282M short-term inv. | $448M-$583M operating cash flow | report ↗ |
| 2024-Q4 | $658M | — | $1.1B+ $252M short-term inv. | —$92M operating cash flow | report ↗ |
| 2024-Q3 | $467M | $224M | $198M+ $1.0B short-term inv. | —-$71M operating cash flow | report ↗ |
| 2024-Q2 | $363M | $180M | $384M+ $1.1B short-term inv. | —$15M operating cash flow | report ↗ |
| 2024-Q1 | $413M | $200M | $427M+ $963M short-term inv. | —-$242M operating cash flow | report ↗ |
| 2023-Q3 | $332M | $194M | $542M+ $1.2B short-term inv. | $41M-$115M operating cash flow | report ↗ |
| 2023-Q2 | $261M | $242M | $852M+ $1.0B short-term inv. | $24M-$122M operating cash flow | report ↗ |
| 2023-Q1 | $254M | $246M | $872M+ $1.0B short-term inv. | $517M-$209M operating cash flow | report ↗ |
| 2022-Q3 | $230M | $217M | $1.0B+ $1.0B short-term inv. | $258M-$65M operating cash flow | report ↗ |
| 2022-Q2 | $233M | $252M | $869M+ $1.1B short-term inv. | $231M-$67M operating cash flow | report ↗ |
| 2022-Q1 | $211M | $194M | $1.2B+ $780M short-term inv. | $105M-$101M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $2.2B | $1.5B | $801M+ $138M short-term inv. | $178M-$205M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $1.9B | $805M | $1.1B+ $252M short-term inv. | —-$206M operating cash flow | report ↗ |
| 2023-FY | $1.2B | $877M | $428M+ $1.2B short-term inv. | $134M-$501M operating cash flow | report ↗ |
| 2022-FY | $933M | $877M | $967M+ $1.0B short-term inv. | $176M-$325M operating cash flow | report ↗ |
| 2021-FY | $702M | $771M | $2.1B+ $0 short-term inv. | $105M-$443M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($417K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-04 | Rodino-Klapac Louise · President, R&D and Tech Ops | Tax withholding | 21,423 | $22.22 | $476K | Form 4 |
| 2026-09-04 | Rothfuss Cristin · EVP, General Counsel | Tax withholding | 22,025 | $22.22 | $489K | Form 4 |
| 2026-09-04 | Estepan Ian Michael · Chief Operating Officer | Tax withholding | 24,799 | $22.22 | $551K | Form 4 |
| 2026-09-04 | Wong Ryan Ho-Yan · Chief Financial Officer | Tax withholding | 13,272 | $22.22 | $295K | Form 4 |
| 2026-07-28 | SEVERINO MICHAEL · director, Chief Executive Officer | Award / grant | 756,104 | — | — | Form 4 |
| 2026-07-28 | SEVERINO MICHAEL · director, Chief Executive Officer | Award / grant (derivative) | 2,224,342 | — | — | Form 4 |
| 2026-06-04 | Barry Richard · director | Award / grant | 16,875 | — | — | Form 4 |
| 2026-06-04 | Chambers Michael Andrew · director | Award / grant | 16,875 | — | — | Form 4 |